Academic Journal
RADI-15. Radiotheranostic Approach in Brain Tumor
| العنوان: | RADI-15. Radiotheranostic Approach in Brain Tumor |
|---|---|
| المؤلفون: | Nemati, Reza, Rekabpour, Seyed Javad, Jokar, Narges, Ahmadzadehfar, Hojjat, Shooli, Hossein, Jafari, Esmail, Assadi, Majid |
| المصدر: | Neuro-Oncology Advances ; volume 3, issue Supplement_3, page iii21-iii21 ; ISSN 2632-2498 |
| بيانات النشر: | Oxford University Press (OUP) |
| سنة النشر: | 2021 |
| الوصف: | Purpose The aim of this study is feasibility and potential treatment of targeted radionuclide theranostic approach for patients with brain tumors. Methods For the period 2020–2021, 6 child and adult patients who had been diagnosed with brain tumors were treated using theranostic approach followed by refractory to conventional therapy. Two patients that were presented with HER-2 positive, ER and PR negative breast cancer and brain metastases as well as a history of several cycles of chemotherapy sessions and radiotherapy using gamma knife were treated with 177Lu-Trastuzumab (Herceptin). Three other patients with primary brain tumor underwent peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE. The last case was a patient with refractory primary cerebral lymphoma to standard therapy with confirmed CD20-positive B-cell lymphoma who underwent 177Lu-Rituximab. Results A two women with HER-2 positive breast cancer and brain metastasis underwent two cycles of 177Lu-trastuzumab. Post-therapy assessment showed some improvement. Next, a man with a high-grade glioma tumor in the left frontal lobe with history of debunking surgery in combination with chemoradiation received 177Lu-DOTATATE that resulted in a short-term stable situation. Another patient presented with a right cerebellopontine angle meningioma underwent PRRT with 177Lu-DOTATATE. She had a stable disease with some improvement in the clinical status. Also, a girl with an astrocytoma in suprasellar cistern underwent 2 cycles of 177Lu-DOTATATE. The complete response was designed. Finally, a patient with refractory primary cerebral lymphoma received 177Lu-Rituximab. Conclusion Nuclear oncology in the field of neuro-oncology (neuroradiotheranostics) has been toward a personalized approach, effective and safe therapy. These preliminary studies might demonstrate feasibility and therapeutic potential of theranostics in patients with primary, relapsed or metastasis brain tumors. Further studies preferentially well-designed multicenter international ... |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.1093/noajnl/vdab071.085 |
| الاتاحة: | http://dx.doi.org/10.1093/noajnl/vdab071.085 http://academic.oup.com/noa/article-pdf/3/Supplement_3/iii21/39606831/vdab071.085.pdf |
| Rights: | http://creativecommons.org/licenses/by-nc/4.0/ |
| رقم الانضمام: | edsbas.B823F9E4 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1093/noajnl/vdab071.085 |
|---|